{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:26:56Z","timestamp":1791581216305,"version":"4.3.4"},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,10]],"date-time":"2023-12-10T00:00:00Z","timestamp":1702166400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.vaccine.2023.12.019","type":"journal-article","created":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T08:34:02Z","timestamp":1703234042000},"page":"713-722","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["An enveloped virus-like particle alum-adjuvanted cytomegalovirus vaccine is safe and immunogenic: A first-in-humans Canadian Immunization Research Network (CIRN) study"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3270-7345","authenticated-orcid":false,"given":"Joanne M.","family":"Langley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soren","family":"Gantt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0525-589X","authenticated-orcid":false,"given":"Scott A.","family":"Halperin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3251-958X","authenticated-orcid":false,"given":"Brian","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelly","family":"McNeil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyun","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1350-9431","authenticated-orcid":false,"given":"David E.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Diaz","family":"Mitoma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.vaccine.2023.12.019_b0005","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1128\/CMR.00062-12","article-title":"The \u201csilent\u201d global burden of congenital cytomegalovirus","volume":"26","author":"Manicklal","year":"2013","journal-title":"Clin Microbiol Rev"},{"issue":"1","key":"10.1016\/j.vaccine.2023.12.019_b0010","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1186\/s12889-022-13971-7","article-title":"A systematic literature review of the global seroprevalence of cytomegalovirus: possible implications for treatment, screening, and vaccine development","volume":"22","author":"Fowler","year":"2022","journal-title":"BMC Public Health"},{"issue":"4","key":"10.1016\/j.vaccine.2023.12.019_b0015","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/rmv.535","article-title":"Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection","volume":"17","author":"Kenneson","year":"2007","journal-title":"Rev Med Virol"},{"issue":"6","key":"10.1016\/j.vaccine.2023.12.019_b0020","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/TP.0000000000002191","article-title":"The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation","volume":"102","author":"Kotton","year":"2018","journal-title":"Transplantation"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2023.12.019_b0025","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1093\/infdis\/jiz448","article-title":"Preventing Infection by Human Cytomegalovirus","volume":"221","author":"Plotkin","year":"2020","journal-title":"J Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2023.12.019_b0030","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.1093\/infdis\/jiz447","article-title":"The Status of Vaccine Development Against the Human Cytomegalovirus","volume":"221","author":"Plotkin","year":"2020","journal-title":"J Infect Dis"},{"issue":"10253","key":"10.1016\/j.vaccine.2023.12.019_b0035","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S0140-6736(20)31868-7","article-title":"Valaciclovir to prevent vertical transmission of cytomegalovirus after maternal primary infection during pregnancy: a randomised, double-blind, placebo-controlled trial","volume":"396","author":"Shahar-Nissan","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2023.12.019_b0040","unstructured":"Guidance for Industry Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trial; 2007."},{"key":"10.1016\/j.vaccine.2023.12.019_b0045","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/978-1-0716-1111-1_19","article-title":"Recent Approaches and Strategies in the Generation of Anti-human Cytomegalovirus Vaccines","volume":"2244","author":"Boppana","year":"2021","journal-title":"Methods Mol Biol"},{"issue":"1","key":"10.1016\/j.vaccine.2023.12.019_b0050","first-page":"1","article-title":"Human cytomegalovirus (HCMV) infection\/re-infection: development of a protective HCMV vaccine","volume":"42","author":"Gerna","year":"2019","journal-title":"New Microbiol"},{"key":"10.1016\/j.vaccine.2023.12.019_b0055","first-page":"16","article-title":"Promising Cytomegalovirus-Based Vaccine Vector Induces Robust CD8+ T-Cell Response","volume":"20","author":"Liu","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10.1016\/j.vaccine.2023.12.019_b0060","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abf3178","article-title":"Prefusion structure of human cytomegalovirus glycoprotein B and structural basis for membrane fusion","volume":"7","author":"Liu","year":"2021","journal-title":"Sci Adv"},{"issue":"1","key":"10.1016\/j.vaccine.2023.12.019_b0065","doi-asserted-by":"crossref","first-page":"e1011107","DOI":"10.1371\/journal.ppat.1011107","article-title":"A single, improbable B cell receptor mutation confers potent neutralization against cytomegalovirus","volume":"19","author":"Jenks","year":"2023","journal-title":"PLoS Pathog"},{"issue":"3","key":"10.1016\/j.vaccine.2023.12.019_b0070","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.3390\/v6031346","article-title":"HCMV infection of human trophoblast progenitor cells of the placenta is neutralized by a human monoclonal antibody to glycoprotein B and not by antibodies to the pentamer complex","volume":"6","author":"Zydek","year":"2014","journal-title":"Viruses"},{"issue":"2","key":"10.1016\/j.vaccine.2023.12.019_b0075","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1128\/CVI.00662-13","article-title":"Enveloped virus-like particle expression of human cytomegalovirus glycoprotein B antigen induces antibodies with potent and broad neutralizing activity","volume":"21","author":"Kirchmeier","year":"2014","journal-title":"Clin Vaccine Immunol"},{"issue":"12","key":"10.1016\/j.vaccine.2023.12.019_b0080","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.2217\/fvl.13.106","article-title":"Developing a Vaccine against Congenital Cytomegalovirus (CMV) Infection: What Have We Learned from Animal Models? Where Should We Go Next?","volume":"8","author":"Schleiss","year":"2013","journal-title":"Future Virol"},{"key":"10.1016\/j.vaccine.2023.12.019_b0085","unstructured":"U.S. Department of Health and Human Services. Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. In: Administration. FaD, editor. Rockville, MD: U.S. Department of Health and Human Services; 2007. p. 10."},{"issue":"1","key":"10.1016\/j.vaccine.2023.12.019_b0090","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.vaccine.2007.10.048","article-title":"Humoral immunity targeting site I of antigenic domain 2 of glycoprotein B upon immunization with different cytomegalovirus candidate vaccines","volume":"26","author":"Axelsson","year":"2007","journal-title":"Vaccine"},{"issue":"35","key":"10.1016\/j.vaccine.2023.12.019_b0095","doi-asserted-by":"crossref","first-page":"4988","DOI":"10.1016\/j.vaccine.2021.07.034","article-title":"An enveloped virus-like particle vaccine expressing a stabilized prefusion form of the SARS-CoV-2 spike protein elicits highly potent immunity","volume":"39","author":"Fluckiger","year":"2021","journal-title":"Vaccine"},{"issue":"37","key":"10.1016\/j.vaccine.2023.12.019_b0100","doi-asserted-by":"crossref","first-page":"5580","DOI":"10.1016\/j.vaccine.2018.07.056","article-title":"Novel trimeric human cytomegalovirus glycoprotein B elicits a high-titer neutralizing antibody response","volume":"36","author":"Cui","year":"2018","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2023.12.019_b0105","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1399-3062.2010.00563.x","article-title":"Lack of antibodies against the antigen domain 2 epitope of cytomegalovirus (CMV) glycoprotein B is associated with CMV disease after renal transplantation in recipients having the same glycoprotein H serotypes as their donors","volume":"13","author":"Ishibashi","year":"2011","journal-title":"Transpl Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2023.12.019_b0110","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1093\/infdis\/jiy102","article-title":"Epitope-Specific Humoral Responses to Human Cytomegalovirus Glycoprotein-B Vaccine With MF59: Anti-AD2 Levels Correlate With Protection From Viremia","volume":"217","author":"Baraniak","year":"2018","journal-title":"J Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2023.12.019_b0115","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1016\/j.vaccine.2019.10.046","article-title":"Updates on immunologic correlates of vaccine-induced protection","volume":"38","author":"Plotkin","year":"2020","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2023.12.019_b0120","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1038\/s41467-023-36683-x","article-title":"The cytomegalovirus gB\/MF59 vaccine candidate induces antibodies against an antigenic domain controlling cell-to-cell spread","volume":"14","author":"Gomes","year":"2023","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.vaccine.2023.12.019_b0125","doi-asserted-by":"crossref","first-page":"e1006601","DOI":"10.1371\/journal.ppat.1006601","article-title":"Protective capacity of neutralizing and non-neutralizing antibodies against glycoprotein B of cytomegalovirus","volume":"13","author":"Bootz","year":"2017","journal-title":"PLoS Pathog"},{"issue":"33","key":"10.1016\/j.vaccine.2023.12.019_b0130","doi-asserted-by":"crossref","first-page":"4705","DOI":"10.1016\/j.vaccine.2021.06.033","article-title":"Characterization of gH\/gL\/pUL128-131 pentameric complex, gH\/gL\/gO trimeric complex, gB and gM\/gN glycoproteins in a human cytomegalovirus using automated capillary western blots","volume":"39","author":"Rustandi","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.12.019_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.coi.2022.102185","article-title":"T cell immunity to cytomegalovirus infection","volume":"77","author":"Zangger","year":"2022","journal-title":"Curr Opin Immunol"},{"issue":"3\u20134","key":"10.1016\/j.vaccine.2023.12.019_b0140","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00430-019-00600-1","article-title":"Role of antibodies in confining cytomegalovirus after reactivation from latency: three decades' resume","volume":"208","author":"Krmpotic","year":"2019","journal-title":"Med Microbiol Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23014524?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23014524?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:33:02Z","timestamp":1759404782000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23014524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S0264410X23014524"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.12.019","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An enveloped virus-like particle alum-adjuvanted cytomegalovirus vaccine is safe and immunogenic: A first-in-humans Canadian Immunization Research Network (CIRN) study","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.12.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}